The Role of Mitochondria in Polycystic Kidney Disease

Polycystic kidney disease (PKD) is a common inherited disorder in which fluid-filled cysts slowly replace normal kidney tissue, eventually causing kidney failure. This 2026 review article synthesizes current evidence on how mitochondria — the cell's energy-producing organelles — go wrong in PKD and actively drive cyst growth and kidney scarring. In PKD, mutations in the PKD1 or PKD2 genes produce faulty versions of proteins called polycystin-1 and polycystin-2, which normally help regulate calcium levels inside cells. When polycystins malfunction, calcium signaling breaks down, mitochondria overproduce damaging reactive oxygen species (ROS), and cells switch from efficient energy burning to a less efficient metabolic program more typical of cancer cells. On top of this, key regulatory switches — including overactivation of the growth-promoting mTORC1 pathway and suppression of the energy-sensing AMPK pathway — compound mitochondrial damage. The review also evaluates emerging treatments that specifically target these mitochondrial problems, such as mitochondrial antioxidants, drugs that restore healthy mitochondrial recycling (mitophagy), and agents that correct the underlying metabolic rewiring. The central message is that mitochondrial dysfunction is not just a bystander in PKD but a core driver of disease progression, making mitochondria a compelling target for future therapies.

• Mutations in PKD1 or PKD2 impair polycystin-1/polycystin-2 function, which directly disrupts intracellular calcium homeostasis and triggers increased production of mitochondrial reactive oxygen species (ROS), reduced oxidative phosphorylation, and promotion of cyst growth and fibrosis.
• Metabolic reprogramming in PKD — a shift away from mitochondrial oxidative phosphorylation toward aerobic glycolysis (a Warburg-like effect) — is mechanistically linked to mTORC1 hyperactivation and AMPK suppression, compounding mitochondrial structural and functional defects including disrupted fission/fusion dynamics and impaired mitophagy.
• Preclinical models show that therapeutic strategies targeting mitochondrial pathways — including mitochondrial-targeted antioxidants, mitophagy modulators, calcium signaling regulators, and metabolic reprogramming agents — demonstrate promise in attenuating cystogenesis and slowing disease progression, although drug specificity and off-target effects remain key translational barriers.

This is a narrative review article that systematically synthesizes published preclinical and clinical evidence on mitochondrial dysfunction in polycystic kidney disease. The authors (affiliated with a Chinese institution, published in the International Journal of Molecular Sciences, May 2026) evaluated studies spanning mitochondrial dynamics, oxidative stress, metabolic reprogramming, calcium signaling, and mitophagy in the context of PKD1/PKD2 mutation-driven disease. No original experimental data, patient cohort, or defined sample size are reported; evidence is drawn from cell-based and animal model studies alongside available human data. The review is scoped to PKD caused by PKD1 or PKD2 mutations and explicitly includes evaluation of emerging mitochondria-targeted therapeutic strategies in preclinical settings.

Because this is a narrative review rather than a primary experimental study, it cannot establish causality, effect sizes, or the relative contribution of individual mitochondrial defects to PKD progression in humans. The therapeutic strategies discussed are largely preclinical, and the review acknowledges that challenges in drug specificity and off-target effects have yet to be resolved for clinical translation. The review does not appear to include a systematic search protocol or meta-analytic methods, leaving it susceptible to selection bias in the literature surveyed. The critical next experiments would be longitudinal interventional studies in validated PKD animal models with mitochondria-targeted agents, followed by early-phase human trials with biomarkers of mitochondrial function as endpoints.

This review extends [§30], which also examines oxidative stress and mitochondrial dysfunction in kidney disease (diabetic nephropathy), by shifting the etiological focus to genetically driven cystogenesis and elaborating the specific role of polycystin-calcium-ROS signaling — a mechanistic angle absent in the diabetic kidney context. It parallels [§99], which investigates mitochondrial dysfunction as a driver of inflammation and senescence through mtRNA release during aging, sharing a core interest in how mitochondrial ROS and quality-control failures propagate pathological signaling beyond the organelle itself. The PKD review also parallels [§27], which dissects mitochondrial transfer defects in Alzheimer's disease via the CD38-Miro1 axis, insofar as both articles frame organ-specific disease progression through the lens of mitochondrial calcium dysregulation and impaired organelle quality control, despite operating in entirely distinct tissue systems. Collectively, this article strengthens the corpus-wide argument that disrupted mitophagy and metabolic reprogramming are convergent disease mechanisms across neurological, inflammatory, and now hereditary renal conditions.

• Mitigating Mitochondrial RNA Release During Aging to Control Inflammation and Senescence
  Both articles center on mitochondrial dysfunction driving chronic disease progression through ROS overproduction and impaired quality control; comparing them reveals how mtRNA-mediated inflammation in aging (id=99) may share mechanistic ground with polycystin-driven mitochondrial stress in PKD.
• 1,25-Dihydroxyvitamin D3 mitigates high glucose-induced oxidative stress, inflammation, and extracellular matrix accumulation in glomerular mesangial cells via the ROS/TXNIP/NLRP3 pathway
  Directly comparable renal disease context — id=30 covers mitochondrial oxidative stress and dysfunction in diabetic nephropathy, allowing readers to contrast how a metabolic insult versus a genetic (PKD1/PKD2) insult converge on similar mitochondrial pathology in the kidney.
• Dysfunction of the CD38-Miro1 Axis Disrupts Astrocyte-neuron Mitochondrial Transfer in Alzheimer's Disease: Mechanisms and Therapeutic Restoration
  Both reviews examine how mitochondrial calcium dysregulation and quality-control failures drive organ-specific neurodegeneration (AD) versus cystogenesis (PKD), making a side-by-side comparison useful for understanding how polycystin-calcium signaling compares mechanistically to CD38-Miro1-dependent calcium handling.
• Small extracellular vesicle signaling and mitochondrial transfer reprogram T helper cell function in human asthma
  id=28 examines mitochondrial dysfunction and extracellular vesicle-mediated immune reprogramming in asthma; comparing it with this PKD review illustrates how mitochondrial ROS and metabolic rewiring serve as a common immunopathogenic currency across genetically versus environmentally driven diseases.
• Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial
  id=98 reports a placebo-controlled trial of urolithin A — a mitophagy activator — providing rare clinical-translation data directly relevant to the mitophagy-modulator therapeutic strategy advocated in this PKD review, enabling readers to benchmark preclinical PKD claims against human trial feasibility.